Objectives. The aim of this study was to confirm the implication of macrophage migration inhibitory factor (MIF) gene in SSc susceptibility or clinical phenotypes in a large European population.
Introduction
SSc, or scleroderma, is a complex polygenic autoimmune disorder, characterized by fibrotic collagen deposition and vascular damage [1] . Clinical manifestations and outcome vary among patients, who are commonly classified into two major subgroups: lcSSc and dcSSc, the latter having a worst prognosis [1] . Detection and quantification of auto-antibodies are among the main routine diagnosis tests in SSc, especially ACA and anti-topoisomerase (anti-Scl70) [1] .
During the past few years, our understanding of the genetic basis of SSc has increased rapidly thanks to large and well-powered candidate gene association studies as well as genome-wide association studies [2] . However, most of the early studies aiming to dissect the SSc genetic component were limited by the inclusion of small sample sizes and the lack of replication of primary associations in independent populations. Along these lines, the macrophage migration inhibitory factor (MIF) gene was associated with SSc clinical phenotypes in a North American Caucasian population [3] .
MIF is a pleiotropic cytokine that has relevant pro-inflammatory and immunoregulatory functions, being an important mediator of innate and adaptive immune responses, as well as tissue-specific mechanisms of damage [4] . MIF has been implicated in the pathogenesis of rheumatic diseases including RA and SLE, among others [5] . Interestingly, recent data suggest that MIF is also implicated in the pathogenesis of SSc [6, 7] . Thus, MIF seems to contribute to vasculopathy in SSc [6] and increased MIF expression levels have been reported in blood of SSc patients [6, 7] . Several polymorphisms have been described within the MIF promoter region. Among them, the presence of the minor allele of a single nucleotide polymorphism (SNP) at À173 (rs755622) creates an activator protein 4 (AP-4) transcription factor binding site [8] and has been correlated with an increased serum and synovial level of MIF [9] . On this basis, we aimed to investigate the association of MIF À173 promoter polymorphism with SSc genetic predisposition or clinical phenotypes, in order to provide a better understanding of the implications of the MIF gene in SSc and confirm previous findings.
Patients and methods

Subjects
We performed a casecontrol association study in eight European populations of white Caucasian ancestry, including a total of 3800 SSc patients and 4282 healthy controls from Spain, Germany, The Netherlands, Belgium, Italy, Sweden, the UK and Norway. All the patients fulfilled the 1980 ACR classification criteria for SSc and were classified as having limited or diffuse SSc as previously described [10] .
The control population consisted of unrelated healthy individuals recruited in the same geographical regions as SSc patients, matched by age, sex and ethnicity with the SSc patient groups. The study was approved by local ethical committees from all the participating centres. Both patients and controls were included in the study after written informed consent.
À173 MIF genotyping
DNA from patients and controls was obtained using standard methods. The À173G/C MIF SNP (rs755622) was selected as genetic marker. The MIF À173 genotyping was performed by a TaqMan SNP genotyping assay (Part number: C_2213785_10) in a 7900HT Real-Time PCR System from Applied Biosystems following the manufacturer's suggestions (Foster City, CA, USA). Genotyping call rate was 95% for MIF À173 SNP. For the pooled analysis, a 98% power was estimated considering the full set of patients and controls.
Results
Both patients and controls were found to be in HWE in all populations considered. We first analysed the cohorts individually and then combined the samples in a pooled analysis. The distribution of MIF À173 genetic variant allelic frequencies in SSc patients and controls, as well as in the different phenotypical and serological SSc subgroups, in each of the considered populations is shown in Table 1 .
The overall allelic distribution in the pooled analysis revealed association of the MIF À173*C allele with SSc susceptibility (P = 0.04, OR = 1.10, 95% CI 1.00, 1.19, P BD = 0.39). After clinical phenotype stratification, the pooled analysis revealed a significantly higher frequency of the MIF À173*C allele in the dcSSc group compared with controls (P = 5.30E-03, OR = 1.21, 95% CI 1.07, 1.38, P BD = 0.89) ( Table 1) . Interestingly, the frequency of the À173*C allele was significantly lower in the lcSSc compared with dcSSc subgroup of patients (P = 0.04, OR = 0.86, 95% CI 0.75, 0.99, P BD = 0.77).
In order to strengthen this subtype-influenced association, we performed a meta-analysis including previous results from Wu et al. [3] . This analysis corroborated that the À173*C allele was significantly under-represented in the lcSSc compared with dcSSc subgroup (P = 0.005, OR = 0.83, 95% CI 0.73, 0.94, P BD = 0.55) (Fig. 1) . No significant differences were observed when considering SSc auto-antibody subgroups.
Discussion
Association studies of functional candidate genes aim to dissect, in a powerful and direct way, the genetic component of human complex diseases. However, validation of initial association reports through independent replication studies in different populations is required to strengthen the confidence in these findings. Along these lines, a recent report showed a protective association of the MIF À173*C allele with lcSSc subtype in a North American population [3] .
In order to confirm the influence of MIF promoter polymorphisms in SSc susceptibility, and provide additional information that could contribute to clarify MIF implication in the disease, we performed an independent association study in a large European casecontrol set including eight European populations. Our study revealed that the MIF À173*C genetic variant seems to be a genetic risk factor predisposing to dcSSc and highlights significant differences between dcSSc and lcSSc phenotypical subgroups. Similar to our findings, in a previous report by Wu et al. [3] , an increased frequency of the À173*C allele in the dcSSc subgroup of patients was observed, although this difference did not reach statistical significance. We consider that this lack of association may be due to low statistical power, since the population size included in Wu et al. study reached only 25% power to detect an association considering OR = 1.20 and À173 MAF = 0.19.
However, in both Wu et al. [3] and the present study, a lower representation of the MIF À173*C allele in the lcSSc compared with dcSSc subgroup of patients is observed. This tendency was observed in all the study populations except the Norwegian. Since the Norwegian cohort is the smallest population included in the study, the lack of concordance with the rest of casecontrol sets may be probably due to a reduced statistical power in this population. Of note, it has been reported that dcSSc patients have higher MIF serum concentrations than lcSSc patients [6] . Moreover, the authors demonstrated that MIF is produced by perivascular infiltrating mononuclear cells in skin specimens of dcSSc, where it could play an important role on the inflammatory stage of vasculopathy by inducing adhesion molecules on endothelial cells. In fact, in this case, digital and pulmonary vasculopathies seem to be influenced by MIF expression [6] . On this basis, it could be speculated that MIF high expression alleles are responsible for the increased MIF levels observed in dcSSc patients, and could play an important role in the progress and vasculopathy of this disease. The MIF subtype-influenced association could be considered as a molecular prognostic tool for SSc patients. Nevertheless, additional functional studies are still required in order to elucidate the exact pathological pathway by which MIF is influencing the development of dcSSc.
MIF has recently been suggested as an interesting therapeutic target, given that it has been shown to promote pro-inflammatory cytokine release and it antagonizes the immune-suppressive effect of glucocorticoids [11] . In fact, its neutralization by specific antibodies provides beneficial effects both in human and animal autoimmune disease studies [5] . The neutralization approach and new innovative perspectives could represent a new opening for SSc and other autoimmune or inflammatory diseases treatment.
On the other hand, confluent evidence indicates the presence of shared genetic factors subjacent to autoimmunity predisposition [12] . Previous findings have shown the implication of MIF À173 promoter polymorphism in different autoimmune diseases, such as SLE [13] , IBD [14, 15] , RA [5, 9, 16, 17] , coeliac disease [18] and psoriasis [19, 20] . This knowledge, together with our findings, designates MIF as a preferential common genetic marker for autoimmunity.
In summary, we provide confirmatory support for the association of the MIF locus with SSc clinical expression, specifically with the dcSSc subgroup of patients. This study could provide guidance to future exhaustive research in genetic composition and phenotypic aspects of SSc. 
Rheumatology key message
. MIF À173 promoter polymorphism is strongly associated with the dcSSc subgroup of patients.
